Cerus Corp

CERSNASDAQ · USD
1.98USD-0.01 (+2.32%)
387

Cerus Corp (CERS) Implied Volatility Current

CERS's 30 day implied volatility is 140.73%, with an IV Rank of 50.40%. This is an average IV Rank versus the past year, meaning Cerus Corp options are fairly priced and currently offer no clear edge to buyers or sellers. CERS's 30 day historical volatility sits at 67.89%, which means implied volatility is running 72.84 points above historical volatility, as of Nov 13, 2026.

Read more

Tracking CERS implied volatility helps you spot when Cerus Corp options are historically cheap or expensive, and where the best trades are hiding. When CERS IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor CERS implied volatility current levels in real time and filter for high probability trades.

Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking CERS IV rank helps you see whether CERS's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced.

Implied Volatility

IV Rank
50.40%IV Rank
Moderate

IV is slightly elevated. Premiums are richer, leaning toward sellers.

Implied Volatility (30d)140.73%

IV Rank50.40%

Historical Volatility (30d)67.89%

IV Minus HV+72.84%

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →